Answers are grounded in this paper and cite their sources.
Follicular lymphoma (FL) is an indolent B cell lymphoma with a heterogenous presentation notable for multiple relapses over a patient’s lifetime. Throughout multiple decades, patients will often require treatments including chemoimmunotherapy, molecularly targeted agents and evolving types of immune therapy. A diverse repertoire of molecularly targeted agents have been studied in FL. Intracellular pathways such as B cell receptor (BCR), PI3K, and BCL2 contribute to follicular lymphomagenesis and multiple agents are utilized to inhibit this pathway. The primary agents which have cleared FDA approval are PI3K inhibitors such as idelalisib, duvelisib, and copanlisib. There remains broad uptake of BTK inhibition with agents such as ibrutinib. Cereblon targeting by lenalidomide affects the tumor micronenvironment and restoration of T and NK cell response. Epigenetic dysregulation is a known clonal defect affecting approximately 70% of FL. The first FDA approved agents is tazemetostat, an EZH2 inhibitor. Notably, EZH2 genetic lesions are observed in approximately 20% of FL and in early trials these patients may have a preferential response to EZH2 inhibition. Aside from lenalidomide and anti-CD20 antibody which have large studies supporting its utilization frontline and second line therapy, the majority of the molecularly targeted agents are used in third line treatment of FL. Except for lenalidomide which is typically combined with anti-CD20 antibodies, the other agents are approved as a single agent therapy. Focused targeted of a single molecular pathways may lead to development of treatment resistance. Therefore, combinations of molecular targeted agents with chemotherapy or immune targeted agents may be favored to reduce development of resistance, achieve deeper remissions and prolong durable responses. This review will highlight the drug class and review the clinical and safety data relevant to FL. Finally, this review will evaluate the available data supporting combination therapy and potential future for synergism for these molecular targeted agents.
No takes yet. Share an insight, caveat, or question.
Batlevi et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: